#HOjournalclub Transcript
Healthcare social media transcript of the #HOjournalclub hashtag.
– ().
See #HOjournalclub Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | Vamsi Velcheti, MD MBA @VamsiVelcheti Hello Welcome Everyone! Excited to join the #HOJournalClub |
 | Mazie Tsang, MD, MAS, MS @MazieTsangMD Still learning the ropes of Twitter, so this is super helpful!! First timer here on #TwitterChats! Another tip I learned along the way is noting multiple parts to a thread, whereas before I painstakingly cut characters so I could fit my comment into one tweet! |
 | HOJournalClub @HOJournalClub @MazieTsangMD Welcome to #HOjournalclub!! Happy you're trying it out! |
| Vamsi Velcheti, MD MBA @VamsiVelcheti #HOJournalClub https://t.co/xgO36t2YVI |
| HOJournalClub @HOJournalClub @VamsiVelcheti We're so pleased you can be our #LCSM expert for the chat! #HOjournalclub |
 | Amar Kelkar, MD, MPH, FACP @amarkelkar @HOJournalClub @amarkelkar 2nd year Heme/Onc at @UFHealthCancer excited to join! #HOJournalClub |
| HOJournalClub @HOJournalClub @Mansourgergi @UVMMedCenter Thanks for joining us! #HOjournalclub |
 | Martina Murphy, MD @DrMMurphy @HOJournalClub Hi all! Welcome to #HOJournalClub! Martina Murphy, Heme/Onc PD from @UFHealthCancer excited to join in! 🐊 |
| Vamsi Velcheti, MD MBA @VamsiVelcheti #HOJournalClub excited to be reviewing this on #worldlungcancerday2019 |
| HOJournalClub @HOJournalClub @MazieTsangMD @UCSFCancer Welcome! #HOjournalclub |
| Vamsi Velcheti, MD MBA @VamsiVelcheti #HOJournalClub Q:1 https://t.co/gJf1XDo4nv |
 | Kara Landry, MD @landry_kara Kara Landry - 1st year heme/onc fellow @UVMLarnerMed Excited to join! #HOjournalclub |
 | Liza Henry McDonald @DocLHenry @HOJournalClub Hey all, Liza from Chicago. PD @LoyolaOnc and excited to be here! #HOjournalclub |
 | Maura (Molly) Barry, MD @doctormb1 RT @HOJournalClub: Welcome to our kick off #HOjournalclub chat! We'll get started with Q1 in a few minutes. In the meantime, please introduce yourself! Trainees, let us know your training level/program! And as always, remember to include #HOjournalclub in all your tweets! https://t.co/1l74NM75go |
 | Natasha Dhawan, MD @NatashaDhawanMD @HOJournalClub Hi all, I'm Natasha, currently a palliative medicine fellow at @DartmouthHitch and applying for heme/onc fellowship this year. Excited to follow along! #HOJournalClub |
 | Ana I. Velázquez Mañana, MD MSc (she/her/ella) @AnaVManana @HOJournalClub Hi all! Ana Velazquez 2nd year fellow @UCSFCancer #HOJournalClub |
| HOJournalClub @HOJournalClub @NatashaDhawanMD @DartmouthHitch Welcome! #HOjournalclub |
| Ana I. Velázquez Mañana, MD MSc (she/her/ella) @AnaVManana RT @HOJournalClub: While we're counting down the last 5 mins, here's a quick review of tips for those of you new to #TwitterChats! #HOjournalclub |
| HOJournalClub @HOJournalClub Alright let's get started! Q1: what do you think of study background, in terms of scientific relevance and patient population? #HOjournalclub |
 | Hamza Hassan @Hamza_HassanMD @HOJournalClub Hello, PGY3 IM resident from upstate Rochester #HOJournalClub. Excited to be a part of this. |
| HOJournalClub @HOJournalClub @XimeJordan Glad you can join in! #HOJournalClub |
| HOJournalClub @HOJournalClub @RiversPharmD @UMNCancer @UMN_Pharmacy Welcome! We're happy to hear your perspectives! #HOJournalClub |
| HOJournalClub @HOJournalClub @VanitaNoronha No worries - that's the best part about #twitterchat - it will still be here when you're free! #HOJournalClub |
 | Ximena Jordan Bruno @XimeJordan RT @HOJournalClub: Alright let's get started! Q1: Alright let's get started! Q1: what do you think of study background, in terms of scientific relevance and patient population? #HOjournalclub |
 | Jonathan Berry @jlberrymd Hi all! PGY-3 from #BIDMC! #HOjournalclub |
| Vamsi Velcheti, MD MBA @VamsiVelcheti Any thoughts on the carbo-taxol-bev backbone for non-squam for the study @PatelOncology @StephenVLiu @DevikaDasMD |
| Vamsi Velcheti, MD MBA @VamsiVelcheti Certainly accceptable but not my preferred regimen for non-squams #HOJournalClub |
 | Steph Trexler @methotrexlerate @VamsiVelcheti #HOJournalClub Similar patient pop as in Keynote-189, but they allowed inclusion of EGFR and ALK alterations which I thought was interesting considering that data had previously shown those pt do not benefit from checkpoint inhibitors |
 | Jean Bustamante-Alvarez MD MS @DoctorJeangoB @HOJournalClub Jean Bustamante Alvarez 3rd year fellow HemOnc fellow Ohio State University #HOjournalclub |
| Vamsi Velcheti, MD MBA @VamsiVelcheti It appears most US oncologists tend to prefer carbo-pemetrexed for non-squamous pts #HOJournalClub |
| HOJournalClub @HOJournalClub Reminder please use A1, A2 etc when responding to Q1, Q2 etc! #HOJournalClub |
| HOJournalClub @HOJournalClub A1: https://t.co/QxyVEsjaaq https://t.co/QxyVEsjaaq |
| Vamsi Velcheti, MD MBA @VamsiVelcheti @StephTrexx Feel the EGFr/ALK subgroup is the most impactful and meaningful data from@this study... will save that for a later discussion Q5 #HOJournalClub |
| HOJournalClub @HOJournalClub @Mansourgergi @VamsiVelcheti, thoughts? #HOJournalClub |
| Natasha Dhawan, MD @NatashaDhawanMD @HOJournalClub A1: Makes sense on physiologic level because we saw Bev inc efficacy of Atezo in other trials and b/c VEGF is involved in EGFR pathway. As far as I can tell, it's a pretty decent sized study population vs. comparable trials + Inclusion of pts w/ EGFR/ALK mutation #HOJournalClub |
| HOJournalClub @HOJournalClub Moving to Q2: Please comment on the strengths/weaknesses of the study design? Consider methods, intervention, and outcomes. #HOjournalclub https://t.co/ssHCNFd2IU |
| Vamsi Velcheti, MD MBA @VamsiVelcheti @HOJournalClub @Mansourgergi Please note the EGFR/ALK population was an exploratory analysis and not part of the ITT population #HOJournalClub |
| Vamsi Velcheti, MD MBA @VamsiVelcheti @PatelOncology @StephenVLiu @DevikaDasMD @RamalingamMD @HornLeora @n8pennell Agree! would have loved to see data with Carbo-pem-bev-aPD1 #HOJournalClub |
| HOJournalClub @HOJournalClub A1 #HOJournalClub |
 | Zach Rivers @RiversPharmD @HOJournalClub A2: investigator-assessed PFS vs central review, even with RECIST criteria, is an interesting choice. Risk for bias vs. logistics? #HOJournalClub |
| HOJournalClub @HOJournalClub RT @RiversPharmD: @HOJournalClub A2: @HOJournalClub A2: investigator-assessed PFS vs central review, even with RECIST criteria, is an interesting choice. Risk for bias vs. logistics? #HOJournalClub |
| Vamsi Velcheti, MD MBA @VamsiVelcheti @StephenVLiu @PatelOncology @DevikaDasMD Can’t agree more.. not a big fan of giving taxol.. i wish we had a study with carbo/pemetrexed/pembro/bev #HOJournalClub especially for EGFR/ALK patients post TKI would love to see a trial |
| Amar Kelkar, MD, MPH, FACP @amarkelkar @HOJournalClub A1. This protocol addresses a population of nonsquamous NSCLC patients excluded by other mutation-specific therapies (e.g. EGFR, ALK). However, there did seem to be a skew in the numbers of Teff-high patients between the two groups that likely affected outcomes. #HOjournalclub |
| Vamsi Velcheti, MD MBA @VamsiVelcheti @PatelOncology @HOJournalClub @Mansourgergi Yes very important to note that patients on the trial were post TKI...#HOJournalClub |
| Natasha Dhawan, MD @NatashaDhawanMD @VamsiVelcheti @HOJournalClub @Mansourgergi This is why I'm a little skeptical.The primary analysis didn't include EGFR/ALK pop & that subgroup was actually quite small given how common it is in NSCLC. Though results are +ve, still think we need a devoted study. They also didn't really get proper TKI trial #HOJournalClub |
| HOJournalClub @HOJournalClub RT @VamsiVelcheti: @PatelOncology @HOJournalClub @Mansourgergi Yes very important to note that patients on the trial were post TKI...#HOJournalClub |
| HOJournalClub @HOJournalClub RT @NatashaDhawanMD: @HOJournalClub A1: @HOJournalClub A1: Makes sense on physiologic level because we saw Bev inc efficacy of Atezo in other trials and b/c VEGF is involved in EGFR pathway. As far as I can tell, it's a pretty decent sized study population vs. comparable trials + Inclusion of pts w/ EGFR/ALK mutation #HOJournalClub |
| HOJournalClub @HOJournalClub RT @VamsiVelcheti: @HOJournalClub @Mansourgergi Please note the EGFR/ALK population was an exploratory analysis and not part of the ITT population #HOJournalClub |
| HOJournalClub @HOJournalClub RT @amarkelkar: @HOJournalClub A1. This protocol addresses a population of nonsquamous NSCLC patients excluded by other mutation-specific therapies (e.g. EGFR, ALK). However, there did seem to be a skew in the numbers of Teff-high patients between the two groups that likely affected outcomes. #HOjournalclub |
| HOJournalClub @HOJournalClub A1 #HOJournalclub |
| HOJournalClub @HOJournalClub @PatelOncology @VamsiVelcheti @Mansourgergi Great comments! Don't forget to include #HOJournalClub and A1/A2/A3 in your responses so we can track the transcript later! |
| HOJournalClub @HOJournalClub A1 #HOJournalclub |
| HOJournalClub @HOJournalClub @StephenVLiu @PatelOncology @VamsiVelcheti @Mansourgergi A1 / #HOJournalClub |
| HOJournalClub @HOJournalClub RT @HOJournalClub: Reminder please use A1, A2 etc when responding to Q1, Q2 etc! #HOJournalClub |
 | Sandip Patel MD @PatelOncology @HOJournalClub The other point is for PD-L1>50% non driver mutation patients, pembro mono (KN24) represents an attractive 1L mNSCLC option in terms of efficacy+toxicity (esp for low volume, asx patients) A1 #HOJournalClub |
| HOJournalClub @HOJournalClub Let's continue with Q3: What were the results of this study? How would you characterize the magnitude of the treatment effect? #HOjournalclub https://t.co/0FHCaXUbDt |
| Sandip Patel MD @PatelOncology @StephenVLiu @VamsiVelcheti @DevikaDasMD Agree, there are ongoing studies of carbo/pem/bev/atezo particularly in post driver mutation setting which should help clarify role for angiogenesis inhibition in era of upfront aPD1 A1 #HOJournalClub |
| Amar Kelkar, MD, MPH, FACP @amarkelkar @HOJournalClub A2. Strengths - The study included quite a large number (though ~400 were in the ACP arm which they deemed inferior before getting into the main analysis) and deals with an unaddressed population. #HOJournalClub |
 | Stephen V Liu, MD @StephenVLiu @HOJournalClub A3/ The study net its primary endpoint, which is important. And while exploratory, the OS benefit in the EGFR subset is potentially the most impactful result and what sets it apart. #HOJournalClub |
| HOJournalClub @HOJournalClub RT @StephenVLiu: @HOJournalClub A3/ The study net its primary endpoint, which is important. And while exploratory, the OS benefit in the EGFR subset is potentially the most impactful result and what sets it apart. #HOJournalClub |
| Sandip Patel MD @PatelOncology @HOJournalClub PFS robust and interim OS positive A3 #HOJournalClub https://t.co/4IAbdwcxVr |
| Vamsi Velcheti, MD MBA @VamsiVelcheti #HOJournalClub |
| Zach Rivers @RiversPharmD @VamsiVelcheti @HOJournalClub Fair, but that’s not something known prior to study. Any of the #Immunotherapy agents with the risk of pseudoprogression worry me in studies, and I think that large-budget studies have the opportunity to alleviate that worry. #HOjournalclub |
| HOJournalClub @HOJournalClub Great discussion so far! Mindful of time will post Q4: what were the major adverse events in this study. Do you think all pt-important outcomes were considered? What are your thoughts on benefits vs harms? #HOjournalclub https://t.co/Gv2uOHQvks |
| Jonathan Berry @jlberrymd @HOJournalClub A3 Interesting and worthwhile to see significant benefit in all groups regardless of PD-LA expression (although benefit definitely seemed greater in those with higher expression). #HOJournalClub |
| Vamsi Velcheti, MD MBA @VamsiVelcheti @PatelOncology @StephenVLiu @DevikaDasMD @christine_lovly Also perhaps more genomic heterogeneity post-TKI progression /? increased TMB #HOJournalClub |
| Steph Trexler @methotrexlerate @HOJournalClub A3 They also saw a benefit in patients with liver mets, which previously was not seen in IMpower130, which I thought implied a benefit in that specific patient group with bevacizumab #HOjournalclub |
| Amar Kelkar, MD, MPH, FACP @amarkelkar @HOJournalClub A2. Weaknesses - There were several opportunities for variance including in the number of treatment cycles (4 or 6 cycles), a protocol change to focus on WT patients, a requirement for NGS prior to population selection, and exclusion of patients with CNS metastases #HOJournalClub |
| Natasha Dhawan, MD @NatashaDhawanMD @HOJournalClub A2: As discussed, some strengths were study size, inclusion of EGFR/ALK pts, and I liked the subgroup analysis by PD-L1 expression #HOJournalclub |
| HOJournalClub @HOJournalClub @StephTrexx @VamsiVelcheti and others: any thoughts on the inclusion of pts with liver meets specifically? #HOJournalClub |
 | Devika Das, MD, MSHQS @DevikaDasMD RT @RiversPharmD: @VamsiVelcheti @HOJournalClub Fair, but that’s not something known prior to study. Any of the #Immunotherapy agents with the risk of pseudoprogression worry me in studies, and I think that large-budget studies have the opportunity to alleviate that worry. #HOjournalclub |
| Vamsi Velcheti, MD MBA @VamsiVelcheti @DevikaDasMD @HOJournalClub Agree IMP150 most won’t change my practice... however am very intrigued by the Bev addition to IO in EGfR patients; have been considering this post TKi for EGFR pts #HOJournalClub |
| Kara Landry, MD @landry_kara A4. Overall it seems like slightly more treatment related adverse events were seen for ABCP vs BCP. #HOJournalClub |
| Amar Kelkar, MD, MPH, FACP @amarkelkar @HOJournalClub A3. There appeared to be a clear median PFS benefit with positive early OS benefit, though the Kaplan-Meier curves showed convergence as time went on between the ABCP and BCP groups especially for OS #HOJournalClub https://t.co/l0R1G0DGnE |
| Natasha Dhawan, MD @NatashaDhawanMD @HOJournalClub A2: Weakness: In the EGFR/AKK population, though they were post TKI, the paper states they had previously receive one or more TKIs, which adds uncertainty/variability in that population. #HOJournalclub |
| Steph Trexler @methotrexlerate @HOJournalClub A4 another potential harm of a 4-drug regimen is less options for subsequent therapy once a patient progresses #HOjournalclub |
| HOJournalClub @HOJournalClub @fernandbteich Welcome! (and good luck with your apps/Match!) #HOJournalClub Feel free to review the Qs and comment! |
| HOJournalClub @HOJournalClub Keep commenting everyone! Here's our final Q5: How applicable are these results in your own practice? Will this change your practice and why? #HOjournalclub https://t.co/jZ8AfmRGhx |
| Ana I. Velázquez Mañana, MD MSc (she/her/ella) @AnaVManana @HOJournalClub A2: I would add issues with applicability at least in the US, given lack of diversity with 80+% of patients on both arms being White #HOJournalClub |
| HOJournalClub @HOJournalClub A5. And we already got a clue from our guest expert @VamsiVelcheti https://t.co/eQIg7C1VZ5 #HOJournalClub |
| Ana I. Velázquez Mañana, MD MSc (she/her/ella) @AnaVManana @HOJournalClub A5: I guess this answers Q5 #hojournalclub |
| Natasha Dhawan, MD @NatashaDhawanMD @anavmanana @HOJournalClub A2: Agreed. This is a huge problem is a significant amount of clinical trials. #HOJournalClub |
 | Jamie Joy @Jamiejoyoncpgx1 A4 def more rash, stomatitis, FN, hemoptysis....also some gr 3/4 hypertension...these are known toxicities of some of the drugs but now need to monitor for all with ABCP combo, also would add #financialtoxicity with this type of regimen #HOjournalclub |
| Ana I. Velázquez Mañana, MD MSc (she/her/ella) @AnaVManana @DevikaDasMD @HOJournalClub A5 also exclusion of patients with CNS mets limits applicability in real world #HOJournalClub |
| HOJournalClub @HOJournalClub @anavmanana A2/A5: Excellent point: how applicable to other demographic subgroups? What differences might we see either other populations? #HOJournalClub |
| Ana I. Velázquez Mañana, MD MSc (she/her/ella) @AnaVManana @NatashaDhawanMD @HOJournalClub 😂 I’m multitasking at its best, attending a patient support group and didn’t want to fully miss #HOJournalClub |
| HOJournalClub @HOJournalClub @Jamiejoyoncpgx1 A4. Quadruple therapy certainly seems tough even with non-overlapping toxicities. #HOJournalClub |
| Amar Kelkar, MD, MPH, FACP @amarkelkar @HOJournalClub A4. The increase in hematologic AEs was notable, especially in the context of using the VEGF inhibitor. Also appetite, nausea, and fatigue. The authors also had to implement changes in screening and excluding patient with high-risk features for pulmonary hemorrhage #HOJournalClub |
| Sandip Patel MD @PatelOncology @VamsiVelcheti @DevikaDasMD @HOJournalClub I think a lot of the studies ongoing like carbo/pem/bev/atezo post osi or upfront osi+bev/ram in EGFR+ will need to show OS for the EGFR+ where we have huge unmet need outside of osi A5 #HOJournalClub |
| HOJournalClub @HOJournalClub RT @PatelOncology: @VamsiVelcheti @DevikaDasMD @HOJournalClub I think a lot of the studies ongoing like carbo/pem/bev/atezo post osi or upfront osi+bev/ram in EGFR+ will need to show OS for the EGFR+ where we have huge unmet need outside of osi A5 #HOJournalClub |
| HOJournalClub @HOJournalClub RT @VamsiVelcheti: @DevikaDasMD @HOJournalClub Agree IMP150 most won’t change my practice... however am very intrigued by the Bev addition to IO in EGfR patients; have been considering this post TKi for EGFR pts #HOJournalClub |
| Vamsi Velcheti, MD MBA @VamsiVelcheti @DevikaDasMD @HOJournalClub I think the post-TKI results are indeed promising but would be very helpful to have a larger phase 3 study perhaps led by cooperative groups #HOJournalClub |
| Sandip Patel MD @PatelOncology @DevikaDasMD @HOJournalClub Interesting biologically but not sure changes treatment decion-making based on current evidence A4 #HOJournalClub |
| Jamie Joy @Jamiejoyoncpgx1 @amarkelkar @HOJournalClub I noticed the GI side effects as well, good point! #HOJournalclub |
| Ana I. Velázquez Mañana, MD MSc (she/her/ella) @AnaVManana @HOJournalClub In the US African Americans have highest incidence of #lcsm and worse survival when compared to other ethnic groups, historically understudied across trials, we need to do better understanding biology diff and increasing access to trials #HOJournalClub |
| Amar Kelkar, MD, MPH, FACP @amarkelkar @DevikaDasMD @HOJournalClub The financial toxicity naturally isn't discussed but definitely worth consideration. The early PFS/OS benefits are eye-catching, especially in the EGFR and liver met subsets, but may yet prove to be transient. #HOJournalClub |
| HOJournalClub @HOJournalClub @StephTrexx A4. Yes, also hard to know the potential value of sequenced Rx, as pts were not allowed crossover to atezo. #HOJournalClub |
| Devika Das, MD, MSHQS @DevikaDasMD RT @anavmanana: @HOJournalClub In the US African Americans have highest incidence of #lcsm and worse survival when compared to other ethnic groups, historically understudied across trials, we need to do better understanding biology diff and increasing access to trials #HOJournalClub |
| Natasha Dhawan, MD @NatashaDhawanMD @DevikaDasMD @anavmanana @HOJournalClub A5: That seemed odd to me as well. To be fair, I haven't read as many lung cancer trials as I definitely will need to going forward, but on my quick review, a # of them (w/ Immunotherapy) had ECOG 0-1 & only a couple with ECOG 2. Is that not the case for others? #HOJournalClub |
| Amar Kelkar, MD, MPH, FACP @amarkelkar RT @VamsiVelcheti: @DevikaDasMD @HOJournalClub Agree IMP150 most won’t change my practice... however am very intrigued by the Bev addition to IO in EGfR patients; have been considering this post TKi for EGFR pts #HOJournalClub |
| Vamsi Velcheti, MD MBA @VamsiVelcheti @NatashaDhawanMD @DevikaDasMD @anavmanana @HOJournalClub I think it would be nice to have a few trials focusing on poor PS and elderly patients #HOJournalClub |
| HOJournalClub @HOJournalClub Thanks for a great discussion everyone! Hope you enjoyed the first chat! Please feel free to keep discussion going. We'll be posting some polls in order to tailor future chats. Info on about our Sept article coming soon! #HOjournalclub https://t.co/IIxII6k4dF |
| Ana I. Velázquez Mañana, MD MSc (she/her/ella) @AnaVManana @NatashaDhawanMD @DevikaDasMD @HOJournalClub majority of trials limit to ecog 0-1, big limitation is majority of met #lcsm patients in real life are really probably ecog 1-2 (mainly 2) #HOJournalClub |
| HOJournalClub @HOJournalClub @VamsiVelcheti @NatashaDhawanMD @DevikaDasMD @anavmanana A5: Hopefully @NCICancerCtrl efforts to relax including criteria for future studies will help! https://t.co/ateevmt8In #HOJournalClub |
| Natasha Dhawan, MD @NatashaDhawanMD @VamsiVelcheti @DevikaDasMD @anavmanana @HOJournalClub A5: Most definitely - geriatric oncology is vital. It represents a much larger portion of our patient population, yet, we tend to test younger/healthier patients in hopes of getting the "best case scenario" results. #HOJournalClub |
| Amar Kelkar, MD, MPH, FACP @amarkelkar @HOJournalClub A5. I haven't seen many patients that fit the stringent study criteria to use this protocol, especially low PS (PS 0/1) patients. Given enough time and under the right circumstances, I'd consider using it, but similar to Dr. @DevikaDasMD I'd be concerned about cost #HOJournalClub |
| HOJournalClub @HOJournalClub Poll 1: We want to make sure everyone has the chance to participate in future chats! Were you able to access tonight's recommended article? If not, please comment if there was a specific barrier. #HOjournalclub |
| Ana I. Velázquez Mañana, MD MSc (she/her/ella) @AnaVManana @HOJournalClub @VamsiVelcheti @NatashaDhawanMD @DevikaDasMD @NCICancerCtrl Agree, same with the amazing expansion of the #gerionc field! #HOJournalClub |
| Devika Das, MD, MSHQS @DevikaDasMD RT @anavmanana: @NatashaDhawanMD @DevikaDasMD @HOJournalClub majority of trials limit to ecog 0-1, big limitation is majority of met #lcsm patients in real life are really probably ecog 1-2 (mainly 2) #HOJournalClub |
| Ana I. Velázquez Mañana, MD MSc (she/her/ella) @AnaVManana @HOJournalClub This was great!!! Looking forward to the next one! #HOJournalClub |
| Maura (Molly) Barry, MD @doctormb1 @HOJournalClub Great discussion! Seems like this will be a great supplement for everyone, since we all know how hard it is to fit in JC at work!!! #hojournalclub #medtwitter Spread the word! |
| Amar Kelkar, MD, MPH, FACP @amarkelkar RT @NatashaDhawanMD: @VamsiVelcheti @DevikaDasMD @anavmanana @HOJournalClub A5: @VamsiVelcheti @DevikaDasMD @anavmanana @HOJournalClub A5: Most definitely - geriatric oncology is vital. It represents a much larger portion of our patient population, yet, we tend to test younger/healthier patients in hopes of getting the "best case scenario" results. #HOJournalClub |
| HOJournalClub @HOJournalClub Poll 2: Does your institution/practice setting hold regular journal clubs? #HOjournalclub |
| Natasha Dhawan, MD @NatashaDhawanMD @HOJournalClub This was awesome! Thank you so much for taking the time to put this together. Looking forward to next month's #HOJournalClub! |
 | LudaBazhenovaMD @LudaBazhenovaMD This study is planned in NCCN TH-138. Called TREAT. |
| LudaBazhenovaMD @LudaBazhenovaMD Atezo instead of pembro |
| HOJournalClub @HOJournalClub Poll 3: Do you regularly participate in other #Tweetchats? (Pro meaning you participate at least 2x/month) #HOjournalclub |
#HOjournalclub content from Twitter.